COMPASS THERAPEUTICS, INC. (CMPX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 12.96M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -81.08M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $12.96M | $-81.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $56.30M | (m) | $10.93M | $-75.17M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $55.97M | (m) | $8.37M | $-72.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $55.34M | (m) | $8.78M | $-71.42M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $51.12M | (m) | $9.74M | $-67.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $45.87M | (m) | $9.07M | $-61.82M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $42.34M | (m) | $8.56M | $-56.63M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $7.92M | $-55.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $7.35M | $-55.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $6.86M | $-53.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $6.12M | $-50.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $5.54M | $-47.86M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $5.21M | $-48.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-44.18M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $5.33M | $-41.66M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-09-30 | (m) | (m) | $5.49M | $-41.77M | $39.00K | (m) | (m) | -1070.97× | Reported |
| 2022-06-30 | (m) | (m) | (m) | $-35.03M | $117.00K | (m) | (m) | -299.37× | Reported |
| 2022-03-31 | (m) | (m) | $4.66M | $-81.72M | $228.00K | (m) | (m) | -358.44× | Reported |
| 2021-12-31 | (m) | (m) | $4.03M | $-81.88M | $370.00K | (m) | (m) | -221.30× | Reported |
| 2021-09-30 | (m) | (m) | $3.89M | $-76.83M | $509.00K | (m) | (m) | -150.94× | Reported |
| 2021-06-30 | (m) | (m) | $5.44M | $-79.94M | $643.00K | (m) | (m) | -124.32× | Reported |
| 2021-06-20 | (m) | (m) | $5.44M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $16.04M | (m) | $4.72M | $-29.32M | $774.00K | (m) | (m) | -37.88× | Reported |
| 2020-12-31 | $14.90M | (m) | $4.02M | $-27.81M | $908.00K | (m) | (m) | -30.63× | Reported |
| 2020-09-30 | (m) | (m) | (m) | $-14.05M | $456.98K | (m) | (m) | -30.74× | Reported |
| 2020-06-30 | (m) | (m) | (m) | $-5.09M | $246.23K | (m) | (m) | -20.68× | Reported |
| 2020-03-31 | (m) | (m) | (m) | $-32.10K | $5.38K | (m) | (m) | -5.97× | Reported |
| 2019-12-31 | (m) | (m) | (m) | $-35.52K | $4.89K | (m) | (m) | -7.26× | Reported |
| 2019-09-30 | (m) | (m) | (m) | $-34.55K | $4.32K | (m) | (m) | -7.99× | Reported |
| 2019-06-30 | (m) | (m) | (m) | $-35.18K | $3.84K | (m) | (m) | -9.16× | Reported |
| 2019-03-31 | (m) | (m) | (m) | $-32.76K | $3.28K | (m) | (m) | -9.99× | Reported |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |